![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Reports Third Quarter 2011 Results
02 nov. 2011 16h15 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the third quarter 2011 and presented a quarterly update on the...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Announces Preliminary Results of Interim Analysis of CH-4051 Phase II Trial in Rheumatoid Arthritis
02 nov. 2011 16h00 HE
|
Chelsea Therapeutics
Mid-Range Dose of CH-4051 Demonstrates Similar Comparable Efficacy and Improved Safety and Tolerability Compared to Standard Dose of Methotrexate
Data From 0.3 mg and 1.0 mg CH-4051 Arms Suggest...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2011 Results
27 oct. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release third quarter results for the period ended September 30, 2011...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Submits New Drug Application for NORTHERA(TM) (droxidopa) for the Treatment of Symptomatic NOH
28 sept. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 28, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics to Present at the 13th Annual Rodman & Renshaw Global Healthcare Investment Conference
07 sept. 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 7, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual Rodman & Renshaw Global Healthcare Investment...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Receives New Patent for Use of Droxidopa in Fibromyalgia
06 sept. 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that the United States Patent and Trademark Office has issued U.S. Patent No....
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics to Present at the Wedbush 2011 Life Sciences Management Access Conference
10 août 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Aug. 10, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Wedbush 2011 Life Sciences Management Access Conference at...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia
08 août 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Reports Second Quarter 2011 Results
26 juil. 2011 16h05 HE
|
Chelsea Therapeutics
Northera™ (droxidopa) New Drug Application for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension on Track for Submission in Third Quarter 2011
Unblinded Interim Efficacy...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Preliminary Data From Exploratory Phase II Study Demonstrates Significant Activity of Droxidopa in Adult Attention Deficit Hyperactivity Disorder (ADHD)
26 juil. 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., July 26, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced positive top-line results of an investigator-led Phase II clinical study of...